MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Salomon Manier, Mai Ngo, Marjohn Armoon, Kasey Bolyard, Fredrik Borgsten, Robin Carson, Sonja Zweegman

Open source

DOI: 10.1038/s41375-026-03128-5
Published: 2026-10-06
Container: Leukemia
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-026-03128-5,
  title = {MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma},
  author = {Thierry Facon and Gordon Cook and Saad Z. Usmani and Cyrille Hulin and Shaji Kumar and Cyrille Touzeau and Nizar J. Bahlis and Supratik Basu and Hartmut Goldschmidt and Hang Quach and Mohamad Mohty and Christopher P. Venner and Katja Weisel and Noopur Raje and Salomon Manier and Mai Ngo and Marjohn Armoon and Kasey Bolyard and Fredrik Borgsten and Robin Carson and Sonja Zweegman},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-026-03128-5},
  url = {https://doi.org/10.1038/s41375-026-03128-5}
}

RIS

TY  - JOUR
TI  - MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma
AU  - Thierry Facon
AU  - Gordon Cook
AU  - Saad Z. Usmani
AU  - Cyrille Hulin
AU  - Shaji Kumar
AU  - Cyrille Touzeau
AU  - Nizar J. Bahlis
AU  - Supratik Basu
AU  - Hartmut Goldschmidt
AU  - Hang Quach
AU  - Mohamad Mohty
AU  - Christopher P. Venner
AU  - Katja Weisel
AU  - Noopur Raje
AU  - Salomon Manier
AU  - Mai Ngo
AU  - Marjohn Armoon
AU  - Kasey Bolyard
AU  - Fredrik Borgsten
AU  - Robin Carson
AU  - Sonja Zweegman
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-026-03128-5
UR  - https://doi.org/10.1038/s41375-026-03128-5
ER  -

APA

Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Touzeau, C., Bahlis, N. J., Basu, S., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Manier, S., Ngo, M., Armoon, M., Bolyard, K., Borgsten, F., Carson, R., & Zweegman, S. (2026). MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma. Leukemia. https://doi.org/10.1038/s41375-026-03128-5

Source records

crossref · retrieved 2026-11-10T01:52:53.800Z